A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy

By Hirbe AC, Eulo V, Moon CI, et al
Published August 28, 2020

Key Takeaways

Among patients with advanced soft-tissue sarcoma (STS) who were deemed not to be candidates for chemotherapy, pazopanib was tested as a first-line agent in this phase II study. Eligibility criteria included: at least 18 years of age, patients should not be candidates for chemotherapy, and should be treatment naive. Pazopanib was titrated from 200 mg twice daily to a goal of 800 mg daily. Clinical benefit rate (CBR) at 16 weeks was assessed as primary endpoint. Median progression-free survival was estimated to be 3.67 (2.62–7.25) months. A median overall survival of 14.16 months was reported, CBR = 39.29% (22/56) (CI = 0.265–0.533). There were no new or unexpected adverse events. Findings demonstrated that front-line pazopanib was beneficial in patients with STS who were not candidates for cytotoxic chemotherapy.

Read the full article on European Journal of Cancer.

Share with emailShare to FacebookShare to LinkedInShare to Twitter